Cargando…
Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613098/ https://www.ncbi.nlm.nih.gov/pubmed/34216384 http://dx.doi.org/10.1007/s40262-021-01055-5 |
| _version_ | 1784603566572306432 |
|---|---|
| author | Ogasawara, Ken Dodds, Michael Mack, Timothy Lymp, James Dell’Aringa, Justine Smith, Jeff |
| author_facet | Ogasawara, Ken Dodds, Michael Mack, Timothy Lymp, James Dell’Aringa, Justine Smith, Jeff |
| author_sort | Ogasawara, Ken |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8613098 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86130982021-12-10 Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma Ogasawara, Ken Dodds, Michael Mack, Timothy Lymp, James Dell’Aringa, Justine Smith, Jeff Clin Pharmacokinet Correction Springer International Publishing 2021-07-03 2021 /pmc/articles/PMC8613098/ /pubmed/34216384 http://dx.doi.org/10.1007/s40262-021-01055-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com[1]mons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Ogasawara, Ken Dodds, Michael Mack, Timothy Lymp, James Dell’Aringa, Justine Smith, Jeff Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
| title | Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
| title_full | Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
| title_fullStr | Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
| title_full_unstemmed | Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
| title_short | Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
| title_sort | correction to: population cellular kinetics of lisocabtagene maraleucel, an autologous cd19-directed chimeric antigen receptor t-cell product, in patients with relapsed/refractory large b-cell lymphoma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613098/ https://www.ncbi.nlm.nih.gov/pubmed/34216384 http://dx.doi.org/10.1007/s40262-021-01055-5 |
| work_keys_str_mv | AT ogasawaraken correctiontopopulationcellularkineticsoflisocabtagenemaraleucelanautologouscd19directedchimericantigenreceptortcellproductinpatientswithrelapsedrefractorylargebcelllymphoma AT doddsmichael correctiontopopulationcellularkineticsoflisocabtagenemaraleucelanautologouscd19directedchimericantigenreceptortcellproductinpatientswithrelapsedrefractorylargebcelllymphoma AT macktimothy correctiontopopulationcellularkineticsoflisocabtagenemaraleucelanautologouscd19directedchimericantigenreceptortcellproductinpatientswithrelapsedrefractorylargebcelllymphoma AT lympjames correctiontopopulationcellularkineticsoflisocabtagenemaraleucelanautologouscd19directedchimericantigenreceptortcellproductinpatientswithrelapsedrefractorylargebcelllymphoma AT dellaringajustine correctiontopopulationcellularkineticsoflisocabtagenemaraleucelanautologouscd19directedchimericantigenreceptortcellproductinpatientswithrelapsedrefractorylargebcelllymphoma AT smithjeff correctiontopopulationcellularkineticsoflisocabtagenemaraleucelanautologouscd19directedchimericantigenreceptortcellproductinpatientswithrelapsedrefractorylargebcelllymphoma |